Celltrion’s Remsima occupies 40% of original drug market in Europe
The number of European patients who were prescribed the Celltrion’s biosimilar antibody Remsima was observed to exceed approximately 105 thousand people as of the 2nd quarter this year.
According to Celltrion, Remsima recorded collective 58 thousand patients in the end of the last year, 82 thous...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
